Regeneron Pharmaceuticals (REGN)

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better.

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth partnership.

Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.

Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Shares took a beating after Eylea sales came in light. Libtayo and Praluent also missed revenue forecasts.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.

A fundamental analysis of (NASDAQ:REGN): Should Quality Investors Include NASDAQ:REGN in Their Portfolio?

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production.

The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.